RANI RANI THERAPEUTICS HLDGS INC

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include:

H.C. Wainwright 26th Annual Global Investment Conference

Location: Lotte New York Palace Hotel, New York, NY

Date: Tuesday, September 10, 2024 at 4:30 pm E.T.

Format: Company Presentation and 1x1 Investor Meetings

Presenter: Chief Executive Officer, Talat Imran

2024 Cantor Global Healthcare Conference

Location: InterContinental Barclay Hotel, New York, NY

Date: Wednesday, September 18, 2024 at 11:30am E.T.

Format: Fireside Chat and 1x1 Investor Meetings

Presenter: Chief Executive Officer, Talat Imran

Interested parties can register for and access the live webcasts for these conferences by visiting the “” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

Media Contact:



EN
03/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RANI THERAPEUTICS HLDGS INC

 PRESS RELEASE

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics to Participate in September Investor Conferences SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include: H.C. Wainwright 26th Annual Global Investment Conference Location: Lotte New York Palace Hotel, New York, NYDate: Tuesday, September 10, 2024 at 4:30 pm E.T.Format: C...

 PRESS RELEASE

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provi...

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed equity offering with gross proceeds of approximately $10.0 million - - Presented clinical and preclinical data on oral delivery of an ustekinumab biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 - SAN JOSE, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“R...

 PRESS RELEASE

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics to Participate in August Investor Conferences SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include: BTIG Virtual Biotechnology ConferenceLocation: Virtual Date: Monday, August 5th – Tuesday, August 6th, 2024Format: 1x1 Investor Meetings Canaccord 44th Annual Growth Confer...

 PRESS RELEASE

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Re...

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics’ Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 446,753 shares of...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch